What’s Propelling CRISPR Therapeutics AG (CRSP) to Reach 52-Week High?

January 14, 2018 - By Vivian Park

The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) hit a new 52-week high and has $31.09 target or 9.00 % above today’s $28.52 share price. The 8 months bullish chart indicates low risk for the $1.17B company. The 1-year high was reported on Jan, 14 by Barchart.com. If the $31.09 price target is reached, the company will be worth $105.30M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 0.28% or $0.08 during the last trading session, reaching $28.52. About 897,001 shares traded or 100.21% up from the average. CRISPR Therapeutics AG (NASDAQ:CRSP) has 0.00% since January 14, 2017 and is . It has underperformed by 16.70% the S&P500.

Analysts await CRISPR Therapeutics AG (NASDAQ:CRSP) to report earnings on March, 9. They expect $-0.74 earnings per share, down 85.00 % or $0.34 from last year’s $-0.4 per share. After $-0.62 actual earnings per share reported by CRISPR Therapeutics AG for the previous quarter, Wall Street now forecasts 19.35 % negative EPS growth.

CRISPR Therapeutics AG (NASDAQ:CRSP) Ratings Coverage

Among 5 analysts covering CRISPR Therapeutics (NASDAQ:CRSP), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. CRISPR Therapeutics has $30 highest and $22 lowest target. $25.17’s average target is -11.75% below currents $28.52 stock price. CRISPR Therapeutics had 5 analyst reports since November 14, 2016 according to SRatingsIntel. The stock has “Overweight” rating by Barclays Capital on Monday, November 14. The stock has “Overweight” rating by Piper Jaffray on Monday, November 14. Citigroup initiated the stock with “Neutral” rating in Tuesday, November 15 report. Guggenheim initiated CRISPR Therapeutics AG (NASDAQ:CRSP) rating on Monday, November 14. Guggenheim has “Buy” rating and $30 target.

More notable recent CRISPR Therapeutics AG (NASDAQ:CRSP) news were published by: Fool.com which released: “Uh-Oh! CRISPR Gene-Editing Stocks May Be Worthless” on January 08, 2018, also Fool.com with their article: “Why CRISPR Therapeutics AG Stock Is Rising Today” published on January 05, 2018, Streetinsider.com published: “Form 4 CRISPR Therapeutics AG For: Jan 05 Filed by: EMSTER KURT VON” on January 12, 2018. More interesting news about CRISPR Therapeutics AG (NASDAQ:CRSP) were released by: Zacks.com and their article: “CRISPR Therapeutics (CRSP) Jumps: Stock Rises 12.1% January 08, 2018” published on January 08, 2018 as well as Seekingalpha.com‘s news article titled: “CRISPR Therapeutics – Corporate Update To Jump Start 2018” with publication date: January 03, 2018.

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 gene-editing platform in Switzerland. The company has market cap of $1.17 billion. The CRISPR/Cas9 technology allows for changes to genomic DNA. It currently has negative earnings. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.